Risk of second primary cancer among patients with early operable breast cancer registered or randomised in Danish Breast Cancer cooperative Group (DBCG) protocols of the 77, 82 and 89 programmes during 1977-2001

By Andersson Michael   Jensen Maj-Britt   Engholm Gerda   Henrik Storm Hans  

Acta Oncologica, Vol. 47, Iss. 4, 2008-01 ,pp. : 755-764

Informa Healthcare

Access to resources Recommend Favorite

Tamoxifen for one year versus two years versus 6 months of Tamoxifen and 6 months of megestrol acetate: A randomized comparison in postmenopausal patients with high-risk breast cancer (DBCG 89C)

By Andersen Jørn   Kamby Claus   Ejlertsen Bent   Cold Søren   Ewertz Marianne   Jacobsen Erik   Philip Preben   Møller Knud   Jensen Disa   Møller Susanne  

Acta Oncologica, Vol. 47, Iss. 4, 2008-01 ,pp. : 718-724

Informa Healthcare

Access to resources Recommend Favorite

DBCG trial 89B comparing adjuvant CMF and ovarian ablation: Similar outcome for eligible but non-enrolled and randomized breast cancer patients

By Ejlertsen Bent   Jensen Maj-Britt   Mouridsen Henning   Andersen Jørn   Cold Søren   Jakobsen Erik   Kamby Claus   Sørensen Peter   Ewertz Marianne  

Acta Oncologica, Vol. 47, Iss. 4, 2008-01 ,pp. : 709-717

Informa Healthcare

Access to resources Recommend Favorite

Adjuvant cyclophosphamide, methotrexate, and fluorouracil in premonopausal patients with node-positive breast cancer: Indirect comparison of dose and schedule in DBCG trials 77, 82, and 89

By Ejlertsen Bent   Mouridsen Henning   Jensen Maj-Britt  

Acta Oncologica, Vol. 47, Iss. 4, 2008-01 ,pp. : 662-671

Informa Healthcare

Access to resources Recommend Favorite

Omitting Axillary Surgery for Low-risk Breast Cancer Patients: A Swedish Prospective Cohort Study

By Arnesson Lars-Gunnar   Ahlgren Johan  

Acta Oncologica, Vol. 39, Iss. 3, 2000-10 ,pp. : 291-294

Informa Healthcare

Access to resources Recommend Favorite